For many years, Crohn’s disease and IBD went widely misunderstood and unrecognized. In fact, early doctors could not differentiate between IBD and diarrheal diseases caused by infectious agents. It wasn’t until 1932 that Crohn’s disease was initially described in detail, but even then, there was little if any effective treatment method. 

Patients were, of course, frustrated by their worsening symptoms and little help from their physicians. Finally, in 1967, the National Foundation for Ileitis and Colitis was established, pushing IBD research and modern medicine forward. 

Implementation of biologics

Biologics were a breakthrough treatment method for IBD. These specialized antibodies work by interrupting immune system signals and reducing the body’s unnecessary inflammatory response. 

Infliximab is one of the most frequently prescribed and effective medications against inflammatory diseases like colitis and Crohn’s disease. The issue is that when it was initially developed, physicians did not understand the drug and the label did not provide information or means to ensure response, leading to high failure rates. Patients would quickly develop anti-drug antibodies, lessening the effects of Infliximab and rendering it ineffective. 

Biologics with iDose

To increase the chances of successful drug therapy, Baysient developed the web-based iDose system, which calculates a precise dose of Infliximab for inflammatory disease patients. It utilizes Bayesian models, routine lab results, and demographics to individualize dosing to a specified target trough level for each individual patient. 

With iDose, the failure rate of Infliximab decreased dramatically, with a much higher chance that it will continue to work for the patient, year after year.  This revolutionary development means that more patients can reach and remain in remission while keeping healthcare costs low for everyone. 

iDose is available for individualized dosing of all marketed MAbs used to treat inflammatory diseases, including IBD, rheumatoid arthritis, and psoriasis. 

Start offering your patients an individualized approach to dosing, and help them reach long-term remission. Schedule your demo with the Baysient team today to get started.